Business Context and Reporting Period
Company: Inmune Bio, Inc. (INMB)
Filing Type: Form 8-K (Current Report)
Date of Report: August 7, 2023
Reporting Period: Second Quarter ended June 30, 2023
Context: The filing serves to announce the Company's financial results for the quarter ended June 30, 2023, and provides a business update via an attached press release (Exhibit 99.1).
Key Financial Metrics
The provided text is a cover sheet and does not contain specific numerical data. The filing references a press release for detailed figures but does not list them directly.
- Revenue: Not provided in this text.
- Profit/Loss: Not provided in this text.
- Cash Flow: Not provided in this text.
- Margins: Not provided in this text.
- Debt and Liquidity: Not provided in this text.
Material Changes
The filing text does not provide specific comparative data or material changes versus the prior period. It only indicates that results for the quarter ended June 30, 2023, were announced.
Guidance, Outlook, and Risks
Management Commentary: The Company issued a press release containing a business update alongside the financial results.
Legal Disclaimer: The information in this Current Report and Exhibit 99.1 is furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934. It is not subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933. Furthermore, this information shall not be incorporated by reference into any registration statement unless expressly set forth by specific reference.
Investor Verification Checklist
- Review the attached Exhibit 99.1 (Press Release dated August 7, 2023) for specific revenue, net loss, and cash position figures, as they are absent from the 8-K cover text.
- Verify the business update details regarding clinical progress or strategic initiatives mentioned in the press release.
- Confirm the liquidity position and runway estimates provided in the full press release to assess capital needs.
- Note that the Company is an emerging growth company and has not elected to use the extended transition period for new accounting standards.